Anti-CGRP compositions and use thereof

Patent metadata

Field	Value
Publication number	US-10214582-B2
Application number	US-201815892858-A
Country	US
Kind code	B2
Filing date	Feb 9, 2018
Priority date	May 20, 2011
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

First claim

What is claimed is:

1. A method of treating, preventing, ameliorating, or reducing pain in a patient experiencing pain or comprising a pain-associated disorder, by administering to said patient an effective amount of a pharmaceutical composition comprising a humanized anti-calcitonin gene related peptide (CGRP) antibody comprising a variable light (V L ) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57, and a variable heavy (V H ) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3 of SEQ ID NO: 58, SEQ ID NO: 59, and SEQ ID NO: 60.

2. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a V L chain polypeptide possessing at least 90% sequence identity to SEQ ID NO: 51 and a V H chain polypeptide possessing at least 90% sequence identity to SEQ ID NO: 53.

3. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a V L chain polypeptide of SEQ ID NO: 51 and a V H chain polypeptide of SEQ ID NO: 53.

4. The method of claim 1 , wherein the humanized anti-CGRP antibody comprises a light chain polypeptide of SEQ ID NO: 52 and a heavy chain polypeptide of SEQ ID NO: 54.

5. The method of claim 1 , wherein said pharmaceutical composition is administered acutely or prophylactically.

6. The method of claim 2 , wherein said pharmaceutical composition is administered acutely or prophylactically.

7. The method of claim 3 , wherein said pharmaceutical composition is administered acutely or prophylactically.

8. The method of claim 4 , wherein said pharmaceutical composition is administered acutely or prophylactically.

9. The method of claim 2 , wherein said pain or pain-associated disorder is associated with elevated CGRP.

10. The method of claim 1 , wherein said pain or pain-associated disorder comprises inflammatory pain.

11. The method of claim 1 , wherein said pain or pain-associated disorder comprises neuropathic pain.

12. A method of treating, preventing, ameliorating, or reducing pain in a patient experiencing pain or comprising a pain-associated disorder, comprising administering to said patient an effective amount of a pharmaceutical composition comprising a humanized anti-calcitonin gene related peptide (CGRP) antibody selected from the group consisting of:
a. a variable light (V L ) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 57, and a variable heavy (V H ) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60;
b. a V L chain polypeptide of SEQ ID NO: 51 and a V H chain polypeptide of SEQ ID NO: 53; and
c. a light chain polypeptide of SEQ ID NO: 52 and a heavy chain polypeptide of SEQ ID NO: 54.

13. The method of claim 12 , wherein the treatment is acute.

14. The method of claim 12 , wherein the treatment is prophylactic.

15. The method of claim 12 , wherein the composition is administered with another anti-CGRP antibody or therapeutic agent.

16. The method of claim 12 , wherein said pain or pain-associated disorder is associated with elevated CGRP.

17. The method of claim 12 , wherein said pain or pain-associated disorder comprises inflammatory pain.

18. The method of claim 12 , wherein said pain or pain-associated disorder comprises neuropathic pain.

19. The method of claim 18 , wherein said neuropathic pain comprises trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarialgia, reflex sympathetic dystrophy, neurogenic pain, sciatica, osteoarthritis or rheumatoid arthritis pain, lower back pain, or diabetic neuropathy.

20. The method of claim 12 , wherein said pain or pain-associated disorder comprises visceral pain.

21. The method of claim 20 , wherein said pain-associated disorder comprising visceral pain comprises gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, or ulcerative colitis.

22. The method of claim 12 , wherein said pain or pain-associated disorder is cancer or tumor pain.

23. The method of claim 12 , wherein said cancer or tumor pain is primary or metastatic bone cancer pain.

24. The method of claim 12 , wherein said pain or pain-associated disorder comprises nociceptic pain.

25. The method of claim 12 , wherein said pain or pain-associated disorder comprises post-operative incision pain.

26. The method of claim 12 , wherein said pain or pain-associated disorder comprises complex regional pain syndrome.

27. The method of claim 12 , wherein said pain or pain-associated disorder comprises dysmenorrhea.

28. The method of claim 12 , wherein said pain or pain-associated disorder comprises osteoporotic fracture pain.

29. The method of claim 12 , wherein said pain or pain-associated disorder comprises burn pain.

30. The method of claim 12 , wherein said pain comprises post-surgical pain.

Assignees

• Alderbio Holdings Llc

Inventors

• Kovacevich Brian Robert
• Garcia-Martinez Leon F
• Anderson Katie Olson
• Dutzar Benjamin H
• Billgren Jens J
• Latham John A
• Mitchell Danielle M
• Mcneill Patricia Dianne
• Janson Nicole M
• Loomis Maria-Cristina

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K16/26 Primary

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• A61K2039/505

  comprising antibodies · CPC title